Compare Ascendis Pharma A/S (ASND) vs Innodata Inc (INOD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Innodata Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Innodata Inc trades at $67.3 (market cap $2.21B). The key difference: Ascendis Pharma A/S is far larger — about 8× Innodata Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals.
| ASND | INOD | |
|---|---|---|
Market Cap | $17.74B | $2.21B |
Sector | Health | Technology |
52-Week High | $277.18 | $121.50 |
52-Week Low | $163.32 | $34.45 |
Enterprise Value | $18.11B | $2.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
INOD trades at $67.80, down 1.99% amid bearish technical signals despite strong fundamental performance. The stock shows robust revenue growth with 2025 revenue of $251.66M and net income of $32.18M, supported by consistent earnings beats. Analyst consensus remains bullish with a $130 price target, though recent insider selling and technical weakness create near-term pressure.
Outlook remains positive given AI-driven growth potential and strong profitability metrics, but investors face volatility risks from high valuation multiples and competitive pressures in the AI data services space. The stock's current pullback presents a potential entry point for long-term investors believing in the AI growth story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
